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Abstract: Drinking alcohol and smoking cigarettes results in the formation of reactive 
aldehydes in the lung, which are capable of forming adducts with several proteins and 
DNA. Acetaldehyde and malondialdehyde are the major aldehydes generated in high levels 
in the lung of subjects with alcohol use disorder who smoke cigarettes. In addition to the 
above aldehydes, several other aldehydes like 4-hydroxynonenal, formaldehyde and acrolein 
are also detected in the lung due to exposure to toxic gases, vapors and chemicals. These 
aldehydes react with nucleophilic targets in cells such as DNA, lipids and proteins to form 
both stable and unstable adducts. This adduction may disturb cellular functions as well as 
damage proteins, nucleic acids and lipids. Among several adducts formed in the lung, 
malondialdehyde DNA (MDA-DNA) adduct and hybrid malondialdehyde-acetaldehyde 
(MAA) protein adducts have been shown to initiate several pathological conditions in the 
lung. MDA-DNA adducts are pre-mutagenic in mammalian cells and induce frame shift 
and base-pair substitution mutations, whereas MAA protein adducts have been shown to 
induce inflammation and inhibit wound healing. This review provides an insight into 
different reactive aldehyde adducts and their role in the pathogenesis of lung disease. 
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1. Introduction 
The lung is a highly specialized organ charged with the principal role of O2/CO2 exchange between 
atmosphere and bloodstream [1]. In addition to this gas exchange, it also serves as an interface 
between host and external environment [1]. In this regard, the lungs can be considered an external 
organ due to continual exposure to ambient air [2]. The enormous surface area of the airways and 
continuous exposure to external air makes the lung vulnerable to numerous inhaled toxicants, gases, 
pathogens and chemicals [2]. All of these exposures make the lung susceptible to varying degrees of 
physical, chemical, and biological insults [3]. To combat these insults and to defend against inhaled 
pathogens and other toxicants, the lung employs a defense mechanism including exhalation, cough 
reflex, ciliary beat, and mucus clearance [4], as well as a highly complex innate immune system 
including airway epithelial cells [5] and resident and recruited leukocytes [2]. This first line of defense is 
later followed by specific acquired immune responses associated with the activation of T and B cells aimed 
against specific antigens [6]. In the case of continuous insults, lung defense is compromised, allowing 
inhaled toxic agents to stimulate the generation of reactive oxygen species (ROS) [7]. These ROS induce 
intracellular responses resulting in the release of pro-inflammatory cytokines and chemokines [7] that 
stimulate the influx of neutrophils and monocytes into the lung [7]. Continuous inhalation of pathogens 
or toxic agents, however, may result in excessive ROS production, leading to chronic inflammation and 
lung injury [8]. If not controlled, these ROS may induce inflammation and DNA damage, inhibit apoptosis, 
and may also activate proto-oncogenes through initiation of several signal transduction pathways [9]. 
Therefore, oxidative stress associated with increased production of ROS in the lung due to various 
toxic inhalants may predispose individuals to lung diseases such as chronic obstructive pulmonary 
disease (COPD) [10]. 
2. Role of Alcohol in Lung Disease 
Chronic alcohol abuse or alcoholism costs about $223 billion annually to the U.S. economy [11] and 
is the fourth leading preventable cause of death, causing more than 88,000 deaths annually [12]. Drinking 
more than two drinks/day for men and one drink/day for women can have deleterious health effects 
and is associated with increased mortality [13]. Alcohol abuse is common among critically ill patients 
and is attributed to about 40% of admissions to the intensive care unit [14]. Tissue injury to liver, 
stomach and brain as well as cancers of the upper aero-digestive tract, stomach, and liver are known 
health risks associated with chronic alcohol consumption [15]. In the lung, alcohol over-consumption 
predisposes the host to infectious diseases such as pneumonia [16], as well as acute respiratory distress 
syndrome (ARDS) [17]. After oral ingestion, less than 10% of alcohol consumed is excreted unchanged 
in urine, sweat and breath [18,19]. In the lung, due to alcohol’s volatility, it diffuses freely from the 
bronchial circulation into the airways, rapidly condenses with decreasing temperature, and deposits 
back onto the airways. This recycling of alcohol vapor (or “rain effect”) potentially results in a high 
concentration of alcohol in the airways [20]. Thus, exhaled alcohol breath tests are commonly used to 
measure alcohol ingestion by law enforcement agencies in estimating blood alcohol levels [21]. 
Bacterial infection and acute lung injury are the most significant pulmonary effects of such alcohol 
abuse [22]. Increased risk for infection with tissue-damaging gram-negative pathogens, such as 
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Klebsiella pneumonia, is common in alcoholic patients [23]. Other risks associated with alcohol abuse 
are aspiration of gastric acid and/or microbes and impairment of mucous-facilitated clearance of bacterial 
pathogens [22]. In part, this explains the increased risk of respiratory infections in individuals with alcohol 
use disorders (AUDs). Alcohol-mediated suppression of host immune response and pathogen-clearing 
function of alveolar macrophages could further explain the increased risk of both bacterial pneumonia 
and tuberculosis [24]. 
Production of white blood cells in the bone marrow and superoxide production in neutrophils are 
also decreased in chronic alcohol consumption [25]. Chronic alcohol consumption increases alveolar 
capillary permeability, protein concentration in the alveolar lining fluid and pulmonary edema formation 
in lung [26]. Chronic alcohol ingestion also depletes the antioxidant, glutathione (GSH), throughout 
the alveolar lining fluid of the lung and within macrophages [17]. Other deleterious effects include 
abnormal synthesis and secretion of lung surfactants and increased apoptosis of type II cells [27]. 
Although alcohol has many adverse effects on lung function, only a limited number of studies have 
examined the biochemical processes involved in the mechanism of such injury. Interaction of alcohol’s 
metabolites with other exposures could be one of several possible causes [28]. Therefore, development 
of alcohol co-exposure markers in the lung could be of interest in understanding the pathogenesis of 
lung disorders associated with alcohol abuse. 
3. Role of Cigarette Smoking in Lung Disease 
Cigarette smoking is the number one preventable cause of death in the United States, resulting in 
480,000 deaths each year [29]. A causal association between cigarette smoking and cancers of lung, 
liver, nasopharynx, oropharynx, and larynx has been established by epidemiological studies [30–32].  
In developed countries, cigarette smoking attributes to approximately 90% of lung cancer cases in 
males and 80% in females [33,34]. The number of cigarettes smoked, inhalation practice, duration and 
early start of smoking are the critical risk factors [35]. Thousands of chemicals contained in tobacco 
smoke are known to have carcinogenic properties and can undergo metabolic activation in tissue 
leading to formation of reactive intermediates [36,37]. Besides being a risk factor for cancer development, 
smoking is also the main cause for COPD development [38]. 
Cigarette smoke contains high concentrations of free radicals in both the gas and tar phases [35]. 
These stable oxidized intermediates induce endogenous oxidative stress and inflammation [39]. 
Oxidative DNA damage and lipid peroxidation (LPO) of cell membranes are important effects of 
cigarette smoke-induced oxidative injury [40]. LPO provides a continuous supply of free radicals for 
the oxidation of polyunsaturated fatty acids in membranes causing oxidative cell damage [41]. 
Cigarette smoke-mediated oxidative stress induces local inflammation resulting in increased numbers of 
macrophages in the lung [42]. These macrophages recruit additional inflammatory cells into the lung 
including neutrophils, monocytes, eosinophils, and T lymphocytes [43]. The result is a destructive 
cascade of exposure of the elastolytic compounds and ROS that destroy the lung structure resulting in 
emphysema and obstructive bronchitis [44]. In addition, high carbonyls content such as acrolein and  
4-hydroxynonenal (4-HNE) in the cigarette smoke also leads to carbonyl stress in the lung [45]. Other 
carbonyl compounds present in cigarette smoke are formaldehyde, acetaldehyde, propanal and 
malondialdehyde [46]. These carbonyls generated as a result of oxidative stress may play an important 
role in the progression of lung disease such as COPD [47]. 
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4. Other Environmental Oxidants 
In recent years, ambient air pollutants and diesel exhaust particles have been linked to oxidative 
damage in cells and in tissue [48]. Air pollutants also contribute to oxidative stress in the pulmonary 
system and play a role in adverse lung effects [49]. Ozone, a secondary air pollutant, is a known 
pulmonary irritant [50]. In addition to a single agent, exposure to combined air pollutants, such as 
ozone and particulate matter (PM), greatly induces pulmonary oxidative stress and inflammation [50]. 
This could explain the association between environmental air pollutants and increase in pulmonary 
diseases and mortality demonstrated by several clinical and epidemiological studies [51–53]. 
5. Source of Aldehydes in the Lung 
Significant amounts of ingested alcohol reach the airways via the bronchial circulation where it is 
either metabolized or is excreted by exhaling the vapor [54]. Although the majority of ingested alcohol 
is metabolized in the liver, the mammalian lung can also metabolize ingested alcohol through the 
action of alcohol dehydrogenase (ADH) to acetaldehyde [54]. Thus, after alcohol consumption, airways 
are exposed to high concentrations of acetaldehyde, a primary metabolite (Figure 1) [55]. In addition to 
ADH, during chronic alcohol consumption, alcohol is metabolized by microsomal cytochrome P450 
2E1 (CYP2E1) and peroxisomes to generate ROS leading to oxidative stress [56]. Human lung cells, 
especially bronchial epithelium, club cells, type II pneumocytes, and alveolar macrophages, have been 
shown to express CYP enzymes [57]. CYP2E1-generated ROS easily react with lipid membranes causing 
LPO [58], which is important in the generation of reactive aldehydes such as malondialdehyde (MDA) 
and other products, like 4-HNE [59,60]. 4-HNE forms Michael adducts with nucleophilic sites in DNA, 
lipids and proteins [60]. Another major source of reactive aldehydes in the lung is from the vapor  
phase of cigarette smoke, which is known to contain several aldehydes including butyraldehyde, 
isobutyraldehyde, propionaldehyde, and acetaldehyde [61]. Among the different aldehydes contained 
in cigarette smoke, acetaldehyde is the major one, presenting in very high concentrations [62] 
(approximately 920 g per cigarette) [63]. Additionally, acetaldehyde is widely used as a natural 
constituent of foods and is present in the environment as a pyrolysis product [64]. Acetaldehyde and MDA 
also are produced in biologically significant amounts during the metabolism of alcohol [65]. Higher 
levels of aldehydes have also been reported in exhaled breath condensate and saliva in current smokers 
and patients with COPD [66,67]. Aldehydes have also been identified in the bronchoalveolar lavage 
(BAL) fluid of animals exposed to ozone [68]. These aldehydes, especially acrolein, MDA, formaldehyde 
and crotonaldehyde, are highly reactive and could form DNA adducts in a variety of human tissues [69]. 
Additionally, significantly elevated levels of DNA adducts and smoking-related protein adducts were 
detected in BAL cells as well as in the bronchial epithelium and the peripheral lung of smokers [70,71]. 
The lung is also vulnerable to oxidative injury as a result of exercise and high altitude exposure due to 
oxidative stress [72]. In addition to the lung, increased MDA levels are also reported in excreted urine 
of patients with COPD after exercise as a result of exercise-induced stress [73]. 
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Figure 1. Generation of lung aldehydes and adduct formation. Alcohol is metabolized by 
alcohol dehydrogenase (ADH) to acetaldehyde (AA). But during chronic alcohol consumption, 
CYP2E1 is induced leading to generation of ROS like superoxide, hydrogen radical and 
hydrogen peroxide. This promotes lipid peroxidation and generation of malondialdehyde 
(MDA) and 4-hydroxynonenal (4-HNE). Cigarette smoke itself contains high concentration 
of AA, acrolein and formaldehyde. In addition to this, smoking cigarettes also induces 
local inflammation in lung causing more generation of ROS. This further promotes lipid 
peroxidation generating more MDA and 4-HNE. Acetaldehyde and MDA could form hybrid 
adduct through Schiff base reaction when 2 mole of MDA react with 1 mole of AA to form 
a stable hybrid adduct [74–77]. 
6. Pathological Implications of Lung Aldehydes 
The accumulation of LPO products in human tissues is a major cause of cellular and tissue 
dysfunction as it may lead to membrane dysfunction and oxidative stress-related diseases [78]. Reactive 
, -unsaturated aldehydes generated as a result of LPO could contribute to vascular disease and other 
oxidative stress-related pathologies due to modification of biomolecules [79]. Because oxidative stress 
plays an important role in the development and/or progression of vascular diseases such as atherosclerosis, 
serum malondialdehyde and malondialdehyde-acetaldehyde levels are used as biological markers of 
oxidative stress [80]. 4-HNE, a highly reactive end product of LPO [10], has been linked to a number 
of pathologies such as alcoholic liver disease, COPD, emphysema, asthma, Alzheimer’s disease and 
Parkinson’s disease [81]. In the lung during oxidative stress, reactive LPO products are degraded very 
slowly, resulting in greater accumulation of these products leading to extensive adduct formation and 
tissue damage [60]. Acetaldehyde may also trigger asthma attacks in individuals with genetic alcohol 
dehydrogenase polymorphisms [82]. Inhalation of acetaldehyde for 30 min causes mild respiratory 
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irritation [83]. Acetaldehyde also has a significant role in the etiology of lung cancer [59]. Aldehydes 
in cigarette smoke are able to induce the pro-inflammatory cytokines, tumor necrosis factor alpha 
(TNF-) and interleukin-6 (IL-6) from macrophages, and the neutrophil chemokine, interleukin-8 (IL-8), 
from human bronchial epithelial cells [84,85]. Aldehydes contained in cigarette smoke have been 
shown to inhibit human neutrophil apoptosis and contribute to neutrophilic accumulation, resulting in 
the delayed resolution of inflammation [86]. Acrolein, one of the major constituents of cigarette smoke, 
is involved in increased mucin production and regulation of lung matrix metalloproteinase 9 (MMP-9), 
which may result in decreased lung function in COPD patients [87]. In addition to this, glutathione  
is irreversibly modified by acrolein and crotonaldehyde in human airway epithelial cells [88]. 
Acetaldehyde is also considered a toxin with epigenetic and genetic effects [89]. Ethanol-induced hepatic 
steatosis, fibrosis, carcinoma and gastrointestinal injury are attributed to alcohol-mediated oxidative 
stress [90]. Lipid peroxidation affects mitochondrial membrane permeability [91]. Similarly, acetaldehyde 
could also inhibit mitochondrial reactions and functions [91]. Acrolein may have a role in epigenetic 
modification as it is known to form adducts with histone protein [92]. In brief, in addition to oxidative 
stress and immune dysfunction, membrane disruption, histone modification and mitochondrial dysfunction 
are other major pathological implications of aldehydes (Table 1). 
Table 1. Lung aldehydes, type of adducts formed and lung effect. 









Oxidative stress [78,79] 
COPD, asthma, emphysema [81,82] 
Mild respiratory irritation [83] 
Release of pro-inflammatory cytokine [84,85] 
Epigenetic and genetic effect [89] 





Damage protein structure and function [93,94] 
Slow cilia beating [95] 
Inhibition of anti-oxidative defense [96] 
Stimulation of fibrogenesis [97,98]  





Base pair mutation [102,103] 
Carcinogenesis [104,105] 




Induce pro-inflammatory chemokine [107] 
Inhibit bronchial epithelial cell wound closure [108] 
Increase influx of neutrophils [74] 
Even though chronic alcohol ingestion and cigarette smoke are two major sources of aldehydes in 
the lung, few studies have been conducted on the co-exposure of alcohol and cigarette smoke in the 
lung. This co-exposure is important because the highest level of aldehydes is generated when lungs are  
co-exposed to cigarette smoke and alcohol [54,109]. This co-exposure often leads to oxidative stress 
resulting in high concentrations of acetaldehyde and malondialdehyde in the lung [109]. Therefore, the 
reactive aldehydes generated in the lung could be related to various lung pathologies associated with 
alcohol abuse and cigarette smoking. 
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7. Lung Aldehydes and Protein Adduction 
 
 
Figure 2. Acetaldehyde and MDA could form hybrid adduct through Schiff base reaction 
when 2 mole of MDA react with 1 mole of AA to form a stable hybrid adduct. Aldehydes 
like AA, MDA, acrolein, 4-HNE and formaldehyde could also form protein adduct and 
DNA adduct. The main reactions involved are Schiff base (involves binding of aldehyde to 
the alpha group of an N-terminal amino acid of the protein) and Michael addition (involves 
of binding of aldehyde on amino groups (Lys and His) or thiols (Cys or GSH) [74–77]. 
Reactive aldehydes are electrophilic and react with a nucleophilic site that donates an electron to 
form a strong covalent bond leading to adduct formation [110]. Generally, one of two chemical reactions 
are involved in adduct formation (Figure 2) [111]. One is a Michael addition, which is the reaction 
between -carbon of aldehydes and nucleophilic groups to form 1,2-addition with the double bond. 
Secondly, there is a base reaction that involves formation of Schiff bases between the carbonyl carbon 
of aldehyde and the primary amino group of lysine or N-terminal residues [112]. Various stable 
and unstable adducts are formed when reactive aldehydes generated covalently bind to amino acid 
residues of proteins [113]. Such adduction may disturb protein cellular functions [93]. Aldehydes 
damage protein structure by forming adducts through covalent bonding with cysteine, lysine or histidine 
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residues [94]. In the lung, both ADH- and CYP2E1-catalyzed metabolism of alcohol is associated with 
generation of acetaldehyde, a reactive aldehyde capable of binding to cellular proteins [58]. Acetaldehyde, 
the first metabolite of alcohol, is highly reactive and forms adducts primarily by binding to reactive 
lysine residues of preferred target proteins [114]. Acetaldehyde also has the ability to covalently bind to 
several proteins that could be detrimental to the protein function [115], due to formation of both stable and 
unstable adducts with various proteins [116]. In addition, other lipid peroxidation-generated aldehydic 
products such as MDA and HNE also form Schiff base adducts with proteins [117]. 
Several proteins such as albumin, tubulin, lipoproteins, collagens and erythrocyte membrane proteins 
serve as targets for aldehyde adduction [118]. Accumulation of acetaldehyde due to excess alcohol 
consumption can lead to increased interaction of this aldehyde with biomolecules [28]. Tobacco smoke 
is another source of oxidative stress in the lung as it induces the production of aldehyde-mediated 
injury through oxidative DNA damage and lipid peroxidation of cell membranes [119]. In addition to 
acetaldehyde, 4-HNE has been known to form protein adducts with insulin and histidine residues in 
proteins [120]. 
8. Pathological Implications of Protein Adducts 
Slow cilia beating and decreases in cilia dynein ATPase activity have been reported as a result  
of acetaldehyde binding with dynein and tubulin proteins important for cilia motion [95]. 
Adduction of acetaldehyde with GSH inhibits the anti-oxidative defense system (AODS) responsible 
for the detoxification of ROS and reactive nitrogen species (RNS) [96]. Stimulation of nuclear  
factor-kappa B (NFB), which regulates the secretion of pro-inflammatory cytokines, is another 
effect of acetaldehyde [121]. Aldehyde products stimulates fibro genesis by increasing the expression 
of connective tissue proteins and extracellular matrix components [97,98] and induces immune 
responses [99–101]. Also, 4-HNE formed during lipid peroxidation after ozone exposure appears to 
form specific protein adducts which is toxic and cause apoptosis of murine lung cells [122]. Acute 
alcohol toxicity may lead to formation of malondialdehyde protein adduct in the muscle [123]. The 
presence of HNE-protein adducts has also been studied in diseases related to oxidative stress such as 
neurodegenerative diseases and atherosclerosis [124]. Similarly, protein adducts of acrolein may have a 
role Alzheimer’s disease, Parkinson’s disease [125], atherosclerosis [126] and chronic obstructive lung 
disease [127]. Exposure of 4-HNE to THP-1 cells resulted in modification of proteins and enzymes 
involved in cytoskeleton organization, stress responses, and other metabolic pathways [128]. MDA and 
4-HNE protein adduct formation in the liver could play an important role in the development and 
progression of alcoholic liver disease [129,130]. In COPD patients, a large number of carbonyl-modified 
proteins has been reported in the peripheral lung tissue and correlated with disease severity measured 
by the decline in forced expiratory volume in 1 second (FEV1) [131]. Aldehyde-modified protein 
formation also has an effect on cellular responses. 4-HNE adduction with extracellular signal-regulated 
kinases (ERK1/2) decreased ERK-1/2 phosphorylation and nuclear localization [132]. Similarly, the 
modification of adenosine monophosphate-activated protein (AMP) kinase with 4-HNE inhibits its 
kinase activity and attenuates downstream AMP kinase signaling pathway in MCF-7 breast cancer 
cells [133]. HNE forms adducts with c-Jun amino-terminal kinases (JNKs) leading to nuclear translocation 
and activation in human hepatic stellate cells [134]. Aldehyde adduct also interferes with the function of 
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extracellular matrix protein, which could lead to the formation of scar tissue in the liver [65]. MDA, 
and 4-HNE modified proteins has also been studied in human eye disease [135]. 
9. Lung Aldehydes and DNA Adduction 
Acetaldehyde is highly reactive and the electrophilic nature of its carbonyl carbon results in  
reactions with DNA, generating DNA adducts [136]. This could explain the cytotoxic, genotoxic, 
mutagenic, and clastogenic nature of acetaldehyde as DNA adduct formation plays a critical role in 
carcinogenesis [104,105]. Most of these effects have been proposed to originate from a variety of  
DNA-acetaldehyde adducts [104]. DNA base deoxyguanosine (dG) is the major target for adduction 
followed by deoxyadenosine (dA) and then deoxycytosine (dC) [137]. Acetaldehyde forms other DNA 
adducts such as N2-ethyl-2'-deoxyguanosine (N2-Et-dG) [138] and 1,N2-propano-2'-deoxyguanosine 
(PDG) [139]. Another well-studied aldehyde-DNA adduct is the crotonaldehyde-derived propano-dG 
(CrPdGs) adduct [136]. MDA, a natural product of lipid peroxidation, is also capable of forming an 
exocyclic DNA adduct named malondialdehyde-deoxyguanosine adduct (M1dG) after its interaction 
with DNA [140]. MDA-DNA adduct is also formed when base propenal intermediate is formed during 
direct DNA oxidation [141]. 4-HNE, a well-known end product of LPO, also forms exocyclic ethanol 
DNA adducts, which are highly carcinogenic [142]. Formaldehyde, an aldehyde contained in cigarette 
smoke, also induces ROS formation in many tissues, which can further interact with DNA [143] 
Malondialdehyde formed in the lung of cigarette smokers could form adducts with DNA bases and 
may damage such macromolecules [39]. 
10. Pathological Implications of DNA Adducts 
DNA damage is one of the important pathological conditions associated with DNA adduct formation 
as this could increase the risk of somatic mutations [106] by inducing base pair mutations and causing 
frame-shift mutations [102,103]. MDA-DNA adducts in a number of tissues, including liver [144], 
breast [145] and oral mucosal cells [146]. Another DNA adduct, M1dG, may be associated with increased 
cancer risk and tumor progression [106]. MDA-DNA adducts might contribute to the cause of  
tobacco-related laryngeal cancer as these adducts have been detected in the bronchial epithelium and in 
the larynx of smokers [39,145]. Also, an increased level of MDA-dA was reported in the larynx of 
subjects with the highest intake of alcohol (>44 g) [147]. M1dG adduct was also detected both in 
human bronchial epithelial cells and mouse lung tissue exposed to alcohol [148]. In addition to lung, 
MDA-DNA adducts were also detected in tissues from patients with breast cancer [145]. A correlation 
was found between CYP2E1, 4-HNE and exocyclic ethanol adducts of adenine and cytosine in 
patients with alcoholic liver disease [149]. M1dG adducts were also detected on leukocytes exposed 
to formaldehyde [140] and industrial air pollution [106]. DNA adducts formed by acetaldehydes could 
prompt replication errors and mutations in oncogenes or onco-suppressor genes, which increases risk 
for carcinogenesis [150]. 
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11. Lung Aldehydes and Hybrid Adducts 
People with AUDs are two to three times more likely to smoke cigarettes than those without  
AUDs [151]. This suggests more frequent and higher rates of cigarette smoking among those with 
AUDs than in the general population [152]. Also a strong correlation exists between alcohol and tobacco 
consumption and heavy drinkers have more trouble quitting smoking than do light drinkers [153]. In 
the lung, a unique aldehyde environment is created during co-exposure to alcohol and cigarette smoke 
due to the generation of a high concentration of aldehydes [74]. For instance, high concentrations of 
acetaldehyde and malondialdehyde were detected in the BAL fluid of mice co-exposed to cigarette 
smoke and alcohol [109]. This elevated level of aldehydes is of importance as it is necessary for the 
formation of the hybrid malondialdehyde-acetaldehyde (MAA) adduct in mouse lung [109]. Formation 
of five different types of protein adducts, acetaldehyde, MDA, MAA, 4-HNE and hydroxyl ethyl 
radical, are reported to form after ethanol consumption [154]. MAA-adducted proteins are highly 
stable and resistant to rapid degradation [109]. This hybrid adduct is composed of a cyclic product 
consisting of two molecules of MDA and one molecule of acetaldehyde as a result of a Schiff base 
reaction described previously [155]. The MAA adduct is highly fluorescent and can be detected for a 
few weeks in the liver as a result of slow degradation [156,157]. In comparison to single exposure to 
alcohol or smoke alone, MAA adducts have been detected only in the lungs of mice exposed to both 
alcohol and cigarette smoke [109]. Different endogenously nucleophilic proteins contained in the lung 
are the target of MAA to form hybrid adducts [109]. Among these, surfactant protein A (SP-A) and 
surfactant protein D (SP-D) synthesized primarily by type II alveolar cell in the alveolus have been 
extensively studied [74,158]. SP-A and SP-D play an important role in innate immunity as they can 
directly kill bacteria, or can act as an opsonizing agent by binding to bacteria subsequently enhancing 
macrophage phagocytosis [159]. MAA-adducted proteins are good ligands for scavenger receptor A 
(SRA; CD204), which are expressed extensively on macrophages and also found on endothelial cells, 
platelets, and epithelial cells [160,161]. MAA stimulates inflammatory responses in airway epithelial 
cells through binding to SRA [158]. Diminished antibody responses to MAA-bovine serum albumin 
(MAA-Alb) in SRA knockout mice have also been previously reported [160]. In addition, pre-treatment 
with SRA-binding ligand, fucoidan, blocked MAA adduct-mediated release of pro-inflammatory 
chemokine IL-8 [107]. 
12. Pathological Implications of Hybrid Adduct 
The hybrid adduct, MAA, has been reported to induce pro-inflammatory responses and delay 
wound healing in airway epithelial cells. MAA adduct stimulates release of the neutrophil chemokine, 
IL-8, when exposed to bronchial epithelial cells [107]. Similarly, intranasal instillation of SPD-MAA in 
mice induced KC (CXCL1), a homolog of human IL-8, in comparison to saline or non-adducted SPD 
control [74]. This elevation in KC release resulted in an influx of neutrophils in the lungs of mice 
instilled with MAA adduct for 3 weeks [74]. MAA adduct-stimulated cytokine release is blocked by 
protein kinase C (PKC) inhibitors, implicating a role for PKC in MAA-adducted protein-stimulated 
IL-8 release from bronchial epithelial cells [107]. MAA adducts have also been shown to inhibit 
bronchial epithelial cell wound closure [108]. MAA adduct-induced inflammation is also mediated 
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through PKC as MAA adducts activate PKC epsilon in tracheal epithelial cells [74,107]. Immunologic 
reactions associated with alcohol-related liver disease and atherosclerosis-induced vascular inflammatory 
injury also have been associated with MAA adduct formation [162,163]. In addition to IL-8, MAA 
adducts have been reported to induce the expression of inflammatory cytokines such as TNF, intracellular 
adhesion molecule and vascular cell adhesion molecule in liver endothelial cells [164]. Increased 
formation of MAA adduct has also been reported in rheumatoid arthritis synovial tissue [165]. MAA 
adducts also induce an antibody response as T helper and cytotoxic T cells exhibit robust antibody 
responses to MAA epitope [166]. Extent of tissue damage in acute injury and chronic disease states such 
as atherosclerosis could be correlated to this antibody response [163]. Circulating MAA-modified proteins 
in the bloodstream could be bound, internalized, degraded and presented to the cells of the immune 
system resulting in an immune response [167]. Formation of MAA adducts with N-terminal and bait 
region of mouse alpha 2 macroglobulin (A2M) has been shown to modulate its proteinase and TGF-b1 
binding function [168]. 
13. Conclusions 
Chronic alcohol consumption and cigarette smoking result in the production of several types of 
aldehyde adducts in the lung. The formation of these adducts leads to impaired function and induces 
inflammation and mutagenesis. Although chronic alcohol abuse predisposes the host to pneumonia and 
ARDS, very few studies have focused on the role of alcohol metabolism in alcohol-induced toxicity 
and its consequences in the lung. Many studies have been directed toward cigarette smoke-induced 
oxidative stress, but it has been shown that alcohol also increases LPO leading to the generation of 
reactive aldehydes such as acetaldehyde and MDA. Because the lung is continuously exposed to high 
concentration of alcohol in heavy drinkers, alcohol significantly contributes to the high level of 
aldehydes detected in the lung. Several mechanisms have been proposed to understand the 
consequences of alcohol-induced liver injury, but only limited studies have been done in the case of 
the lung. Additional studies are required to further clarify the role of alcohol in oxidative stress and 
aldehyde generation in the lung. Additional studies are needed to determine the role of different 
adducts formed in the lung and their role in lung pathogenesis. As ROS-mediated lipid peroxidation is 
a major source of aldehyde generation in lung, it is also important to study different factors that 
stimulate ROS generation. Different reactive aldehydes and adducts formed in the lung could act as 
potential biological markers for the source and degree of lung injury associated with alcohol, cigarette 
smoke and other inhaled environment pollutants. Discovering innovative approaches to better identify 
the mechanisms through which adducts cause lung injury, however, still remains a challenge for 
researchers. Among all adducts, the stability of the MAA hybrid adduct may play a prominent role in 
mediating the long term consequences of chronic alcohol abuse and cigarette smoking with respect to 
the development of respiratory infections as well as emphysema and COPD. Understanding factors 
regulating adduct production and their role in the progression of chronic lung diseases is necessary and 
important in order to develop new therapeutic approaches targeting the formation and accumulation of 
reactive aldehyde adducts for promoting the resolution of lung injury. 
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